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In the United States alone, there are more than 100 distinct SRS centers that treat thousands of patients each year. Patients are treated for diverse indications such as benign and malignant brain tumors, vascular malformations, and functional disorders.
SRS is routinely delivered using several common radiosurgical devices. Despite the exponential growth of radiosurgery in the United States during the past 2 decades, the majority of the radiosurgical literature is composed of single-center retrospective studies.
There are, of course, a small percentage of retrospective multicenter pooled analyses and even fewer prospective randomized clinical trials (RCTs). Some prospective multicenter SRS trials, such as ACOSOG-N0574 and the ROSE (Radiosurgery or Open Surgery for Epilepsy) trial, struggled for years to accrue adequate numbers of patients. Reasons for slow patient accrual include limited numbers of centers, low incidence of the underlying disease, patient unwillingness to be randomly assigned to undergo brain surgery, and clinical equipoise.
Although RCTs can often provide substantial high-level scientific information to a field, there are numerous logistical obstacles to their successful completion. The price for such trials can be on the order of millions of dollars for both direct and indirect costs, which makes them impractical to afford answers to the many questions that remain in the field of SRS. In a recent study, the average price per patient in an RCT was $47,000, and some studies have costs as high as $85,000 per patient. 17 Bringing a new drug or device to the clinic requires $800 million to $2 billion, and RCTs are known to be a major driver in this cost. 17 Prospective, observational registries have become important initiatives for quality improvement and patient safety, and there is a newfound appreciation for the "medicine-based evidence" that can be derived from these studies. 7 A large prospectively collected patient database can also serve as a powerful tool for clinical research. Here, we summarize the development and implementation of a national SRS registry compatible with all contemporary delivery devices.
inception of the srs registry
The American Association of Neurological Surgeons (AANS), under the leadership of Drs. Robert Harbaugh and Jon Robertson, launched the NeuroPoint Alliance (NPA) in 2008. The goal of the NPA is to collect, analyze, and report on the clinical data from US-based neurosurgical practices to ensure and enhance quality of care. Data collection through a prospective audited registry can also serve important research needs in a fashion that RCTs cannot. The NPA helped to bring together national stakeholders, including physicians, health care plans, health systems, and government agencies. 2 In the first 5 months after launching the lumbar spine registry, 1357 patients from 21 sites were enrolled into the lumbar spine module.
14 Of those patients who lived to the 3-month postoperative time point, 90% had follow-up data enrolled in the registry. 14 At approximately that same time point and in much the same fashion, the American Society for Radiation Oncology (ASTRO) and its Radiation Oncology Institute began to develop a prostate cancer registry.
9
After the NPA demonstrated proof of principle with a highly successful lumbar spine registry and ASTRO embarked upon the National Radiation Oncology Registry, other indications for registries began to be explored. Stereotactic radiosurgery was a reasonable topic for a national registry. It has a fairly well-defined set of indications and a robust literature spanning more than 3 decades, thereby making the completion of new RCTs difficult. The SRS approach is a high-technology one, and it had seen fairly rapid growth in the past decade, which made its patient care volume appreciable enough for a registry. Significant variability in treatment indications, techniques, and technology exists within the field of SRS; a registry may help to reduce such variability. Also, there is a relatively narrow field of key stakeholders for SRS, including neurosurgeons, radiation oncologists, health care payers, governmental agencies, and 3 major SRS-device manufacturers.
interdisciplinary collaboration
Stereotactic radiosurgery is performed in a multidisciplinary fashion. Leksell worked for many years with Larsson, a medical physicist, to build the original Gamma Knife unit. 8 Around that same time, innovative work in the field of SRS using heavy particles from cyclotrons was conducted by Raymond Kjellberg and Jacob Fabrikant. In 1983 at a center in Buenos Aires, Argentina, Betti and Derechinsky 4, 5 developed the concept of a dedicated linear accelerator for SRS. That system relied upon a high-voltage linear accelerator, and it used a specialized chair and a Talairach stereotactic frame for the patient. 10 A number of additional innovative developments in linear accelerator-based SRS devices followed from teams including Hartman and Sturm 11 in Heidelberg, Germany, Winston and Lutz 13 in Boston, Massachusetts, Colombo et al. 6 in Vincenza, Italy, Barcia-Salorio in Valencia, Spain, and Podgorsak 15 in Canada. The definition sanctioned by the AANS, Congress of Neurological Surgeons, and ASTRO recommends radiosurgical delivery by a team consisting of a neurosurgeon, a radiation oncologist, and a medical physicist. 3 Similarly, the American College of Radiology recommended a similar multidisciplinary approach to ensure quality of care and went so far as to detail specific responsibilities for the individual members of the multidisciplinary team during the SRS process.
16
Because radiosurgery is performed by clinician partners (neurosurgeons and radiation oncologists), it was natural to extend this partnership to the registry. The AANS reached out to the ASTRO on the SRS registry project. Over time, a partnership for the national SRS registry was forged between the AANS and ASTRO. Both organizations created a joint governance board for the registry. The board comprised equal representation of neurosurgeons and radiation oncologists. Specific aims of the registry were established, including the following: 1) to define national patterns of care in radiosurgery and assess for gaps in treatment quality; 2) to provide benchmark data and quality-improvement tools for clinicians performing radiosurgery; 3) to yield information for clinicians and patients during the treatment process to support informed decision making; 4) to improve health care outcomes and potentially lower the cost of care delivered to patients who undergo radiosurgery; and 5) to provide longitudinal data for outcome-related SRS studies. In particular, the last aim will enable post hoc research queries to be performed with the prospectively collected quality data.
Then, the SRS board created a data dictionary, which is a central repository relating the data, origin, usage, and format of elements comprising the registry. The data dictionary includes nearly 135 separate fields, including patient attributes, radiosurgical parameters, preprocedural and postprocedural clinical features, and radiographic results. A sample of the more than 20-page data-dictionary document is provided in Table 1 . Critical to the assessment of quality and outcomes was neuroimaging analysis. Target tumor volume response can now be measured through the use of imaging analytics applied to standardized Digital Imaging and Communications in Medicine (DICOM) data sets. Uniformity of outcome metrics and analytical tools enables more consistent data and greater validity for the aggregation of data across various SRS platforms and diverse SRS centers. For instance, one SRS team may prescribe a dose to a tumor with no margin, and another may prescribe a dose to a volume encompassing the tumor and a 1-mm, uniform margin. Data collected in the registry include dose-volume histogram information for the dose to a particular volume of the tumor and not the planned treatment volume with its 1-mm gross tumor volumeto-planned treatment volume expansion. Because gross tumor volume-to-planned treatment volume expansion may vary from case to case within an individual center or between different centers, dose-volume histogram data exported to the registry need to be normalized to the target volume and not the planned treatment volume. Consistency of registry data allows for a comparison of "apples to apples" rather than "apples to oranges."
Many elements in the data dictionary can be inserted into the registry database in a semiautomated or automated fashion. Semiautomated or automated population of fields in the registry can occur through data extraction from commonly used SRS software packages (e.g., iPlan or Gamma Plan). However, the registry is not device specific; the data elements are compatible with those in all currently used SRS devices. Of the nearly 135 data fields collected, only 25 fields require manual entry by a clinician. The lessening of the data-entry burden on clinicians will only help to increase the completeness, accuracy, and comprehensiveness of the national registry. At the time of entry, data elements will be checked to ensure that they are within preset reasonable ranges for each field. For example, a dose of 500 Gy will prompt a system response to query the appropriateness of the entry given that it falls outside the range of normal radiosurgical doses. In addition, auditing of the data by an independent clinical trials organization, Quintiles, was put into place to ensure the fidelity of the data. Also, Quintiles will perform queries to sites regarding any missing or seemingly erroneous data, which is important for increasing confidence of outside stakeholders in the reliability of data reported from this registry.
Also, a comprehensive set of rules for the governance of the quality and outcome data gathered as part of the registry was established. Outcomes will need to be risk adjusted rather than simply compared according to mean performance. Clinicians can access their data and compare them with an aggregate of their peers for self-assessment. However, more global access to the data is permitted through a process that requires a scientific proposal and review of the same by the SRS board. Quality and clinical research projects can be undertaken through a process that provides fairness and opportunity for all investigators while ensuring scientific oversight and biostatistical assistance to the endeavors. A firewall exists between corporate partners and the data repository.
The development of the previously successful lumbar spine registry was based upon a subscription model. Thus, clinician users or the health systems for which they worked paid for use of the online database. They also paid for the staff required to enter data into the registry. Whereas such a model proved successful, at least in the short term, for the lumbar spine registry, the model did not seem ideal for a national SRS registry. Moreover, lumbar spine registry fields were populated through manual data entry, which is laborious and prone to error.
Working with corporate partners including Brainlab and later Elekta, a funding model for the registry was established through corporate educational grants to the parent organizations. Other corporate partners have also expressed interest in the registry effort. This level of funding for the SRS registry eliminates the need for a subscription charge to enter data into the registry. The registry also provides funding to pilot sites to offset direct expenses for data collection, much like a funded clinical trial would do. Such a financial strategy represents a novel funding mechanism and unique set of partnerships that may represent a model to inform the design of other observational studies.
It should help to ensure early and more widespread adoption of the registry and improved data fidelity. Also, with their extensive software-engineering experience, the corporate partners created data entry and extraction platforms that were compatible with the majority of SRS devices. Such platforms incorporated features including semiautomated data extraction from the SRS planning software and sophisticated neuroimaging analytics for follow-up assessment of SRS responses (Fig. 1 ). An organizational diagram of the SRS registry is depicted in Fig. 2 . At the onset, the registry will include 30 high-volume SRS sites ( Table 2) . Each of these sites has a volume of more than 100 intracranial SRS cases annually. The sites were selected in part to ensure geographic diversity of patient accrual and to reflect academic, private, and hybrid sites (Fig. 3) . Also, a clinical investigator at each site had to express willingness to participate in the registry. The sites will accrue patients in Year 1 and test the electronic data-capturing software in a fashion that will no doubt lead to further refinements. In Year 2 of the effort and beyond, the SRS registry effort will be expanded further to open additional sites for accrual.
It is anticipated that by Year 3, data from 27,000 patients will have been accrued to the SRS registry, which would make this registry the largest and most comprehensive extant database for SRS clinical outcomes. The statistical power of such a registry is appreciable. Of these 27,000 patients, if we assume that 5000 patients have an indication such as brain metastases and that 50% of patients undergo a particular SRS intervention with a more common outcome event (e.g., 25 per 100 patients), then according to a log-rank test, the study would have 90% power to detect a hazard ratio of 1.22, assuming a 2-sided test and alpha value of 0.05. For a rarer outcome event (e.g., 1 per 100 patients), the same log-rank test would indicate a 90% power to detect a hazard ratio of 4.02 with 5000 patients, again assuming a 2-sided test and an alpha value of 0.05. Thus, the registry should offer "big-data" analytical options for clinicians who perform SRS.
At the end of Year 3 of the registry effort, the aggregate data will be in the public domain and provide health care consumers and other interested parties the opportunity to review and assess the outcomes associated with contemporary SRS.
Maintenance of Certification and the SRS registry
The American Board of Medical Specialties is composed of representatives from individual medical boards including the American Board of Neurological Surgery (ABNS). In 2000, the American Board of Medical Specialties introduced continuous professional learning and development in an initiative called maintenance of certification (MOC). The ABNS MOC process includes evaluation of clinical outcomes derived from the self-reported details of 10 neurosurgical cases spanning a set period.
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The ABNS is presently involved in a reorganization of neurosurgical MOC, particularly MOC Part IV (practice performance). The new MOC process will involve incorporation of multiple novel methods to continuously advance quality improvement, including using patient care registries. The NPA serves as the data-collection partner for the ABNS. Patient-centered and risk-adjusted clinical outcomes can provide the ABNS the ability to assess a neurosurgeon's clinical skills, safety, and quality in his or her practice setting. The integration of the SRS registry into MOC would bring a level of objectivity and subspecialty insight to the assessment of an SRS practice, adding to the value of the MOC process in neurosurgery.
The SRS registry will comprise "real-world" data pertaining to outcomes. Comparing clinicians' outcomes and benchmarking individual surgeons' risk-adjusted outcomes may be an important addition to the ABNS MOC process. The key cases in radiosurgery can be benchmarked more accurately against the larger, aggregate outcomes derived from the national SRS registry. In particular, stratification of outcomes based on key prognostic factors (e.g., intracranial tumor volume, location, and neurological performance status) can provide better comparative assessments of performance. In this fashion, the ABNS MOC process has the potential to lead to quality improvements by clinicians.
Future directions
Radiosurgery represents a paradigm-shifting approach for the disciplines of neurosurgery and radiation oncology. The field continues to evolve in terms of the technology used to deliver it, and the indications for which it is used continue to expand. Over the coming years, the national SRS registry will evolve to meet the needs of a changing field and better serve the clinicians and patients whom it encompasses.
There are some diagnostic gaps in the current SRS registry. For less common indications such as essential tremor, cavernous malformations, gelastic seizures associated with hypothalamic hamartomas, and obsessive compulsive disorder, radiosurgery has shown considerable benefit for selected patients. However, the registry was not initially designed to capture data from patients with these types of diagnoses. The failure to include these rare indications was not inadvertent but intentional. The volumes of patients with these SRS indications are usually low, and the resources required to track their outcomes are often distinctly different from those for other more standard SRS indications. However, these SRS indications remain important ones. Given their rarity, some of these SRS indications may ironically benefit the most from a big-data initiative such as this registry. Quality and outcome improvements can be challenging to achieve when centers encounter such cases only a few times per year. However, by pooling the data, benchmarking for outcomes can help to identify the benefit-to-risk profile for a procedure. The identification of prognostic factors for rare SRS indications can also lead to improved patient selection and appropriate allocation of medical resources. Outcome data from the registry can also lead to more rapid recognition of the value of an SRS procedure and the widespread adoption of the procedure for a newer indication.
Stereotactic radiosurgery is also a field that extends well beyond the border of the United States. In fact, radiosurgery is practiced quite frequently in developed countries such as Japan and France. It is also permeating countries such as those in Africa. 10 The platform, including the data dictionary, the data-entry system, analytics, and the secure repository, is Internet based. The cost of building registries has already largely been paid for through corporate grants and direct support from the 2 professional societies. Expanding the registry's reach beyond the United States to international partners may require a modest investment to scale it up. Accrual of international data would provide even "bigger" data for quality, outcome, and post hoc research. Opportunities for data-driven practice improvement using real-world clinical outcomes could benefit US and international SRS practitioners. Innovations in radiosurgery may be recognized more quickly with the statistical power of a large cohort, and problems associated with a particular technique could also be identified more easily and revised accordingly. Ongoing discussions with international clinical partners about expanding the SRS registry are underway.
Finally, the SRS registry requires a financial model that will enable it to exist in perpetuity. Such a model will continue to require modest investments from corporate partners, clinicians, and professional societies. However, the sources of support for the registry can be diversified to include other groups such as private payers, patients, foundations, and the federal government. The cost of continuing the final registry pales in comparison with the comparable cost of a single RCT.
conclusions
The future of registries in US clinical medicine seems to be a bright one. The multidisciplinary nature of the SRS registry and the financial model that enables its implementation may serve as models for future registry efforts. The real-world data accrued through the registry will help to advance the field of SRS. Quality improvement, innovation, and cost-effective care should be enhanced to the benefit of patients and the clinicians treating them.
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